best practices for adopting a medication use policy ... · pdf filebest practices for adopting...
TRANSCRIPT
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com
Best Practices for Adopting a Medication Use Policy Through a System-Wide P&T Committee Part 2: Medication Use Policy
March 2017
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 2
Objectives
• Describe the role of a system Pharmacy and Therapeutics Committee as a foundation for system medication use policy
• Identify the evolution of medication use policy following implementation/establishment of a system formulary
• Provide examples of initiatives in medication use policy and within other specialties outside of the pharmacy realm
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 3
Rationale for System P&T/Formulary/Medication Use Policy
Standardization
Information Technology
Economic Drivers
Optimizing Medication Use
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 4
System Med Use Policy Rationale- Standardization
• Approach quality measures and safety initiatives from broader perspective
• Identify best practices to meet regulatory standards and system goals
• Learn from successes at one institution and apply to the remainder
• Examples: - glycemic variability – VTE risk assessment – smart pump alert analysis – emergency department protocols – antimicrobial surgical prophylaxis
Improved Quality and Safety
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 5
System Med Use Policy Rationale - IT
• Centralized file build, file maintenance, trouble shooting and clinical decision support developed and maintained by centralized IT staff
• Minimize duplicate builds/work by supporting System P&T-approved initiatives – Order sets, guidelines, interchanges, protocols, formulary products
• Report standardization and analysis – BCMA compliance – drug-drug interaction alerts – alert monitoring (actions taken, fatigue, etc.)
Decrease duplicative work
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 6
System Med Use Policy Rationale - Economic
• Standardized formulary and med management initiatives to meet contract requirements to achieve maximum savings
– IDN contracts – increased buying power for automation
• Staff Allocation: centralize multiple processes to reduce duplicative work
• Facilitates patient transfers and cross coverage
Save Money, Improve Efficiency
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 7
Essential Components
• System P&T Committee and Formulary • System Subcommittees/Work Groups
• Challenges: – Too many groups! – How to ensure participation from ALL sites?? – Piloting initiatives at one site
System Medication Use Policy
Example Subcommittees Example Work Groups Anti-microbial Emergency care Anti-coagulation Immunization Glycemic management Radiology Medication safety Operating room Pain management Etc., etc., etc.!!
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 8
Multi-Phase Implementation
• First Phase: Pharmacy-controlled – Compounding (standard concentrations; BUD; light protection; do not
tube) – Dosing protocols (anticoagulation, aminoglycosides, IV to PO, renal
dosage adjustment) – Delivery systems (IV workflow, ADCs)
• Second Phase: Multi-disciplinary – Medication use guidelines/treatment algorithms – Electronic order sets – Clinical decision support – Safety guidelines (LASA; REMS support; high alert strategies; fall risk
assessment) – Delivery systems (smart pumps, ADCs)
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 10
Example: Anticoagulation Dosing
• Anticoagulation subcommittee (or group of pharmacist subject matter experts and physician champions)
• Find commonalities among existing protocols
• Develop consensus guideline/treatment algorithms
• Define approach: pharmacists manage only patients receiving therapeutic anticoagulants versus ALL patients on all anticoagulants
• Agree on minimal acceptable standard
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 11
Example: Anticoagulation Dosing
• Site departmental/subcommittee approvals
• System P&T approval
• Publish guidelines/consensus
• Education and training (standardized)
• Identify standardized system competencies
• Monitor standardized, pre-determined outcomes
• Wash, rinse, repeat
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 12
Example of Site System QI/MUE Report
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
A
B
C
D
E
System
Adherence to System Dosing Guidelines - IV Heparin
3rd qtr 2nd qtr 1st qtr
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
A
C
E
Adherence to System Dosing Guidelines - Enoxaparin
3rd qtr 2nd qtr 1st qtr
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 13
Example of Site System QI/MUE Report
0% 20% 40% 60% 80% 100%
A
B
C
D
E
System
Rate of Compliance
Completion of Warfarin Counseling
3rd Qtr. 2nd Qtr. 1st Qtr.
0% 1% 2% 3% 4% 5%
A B C D E
System
Incidence of Major Bleeding with Heparin & Warfarin only
3rd qtr. 2nd qtr. 1st qtr.
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 15
Action Pane (within INITIAL assessment page)
Display active VTE prophylaxis treatments
Auto-calculation of total score
Display reference text and the RISK level
Actionable Items:
Place VTE Prophylaxis Power Plan
Document that patient currently has VTE Prophylaxis ordered
Document that VTE prophylaxis not appropriate
Documentation of Contraindications
Allows for Free-text entry
If Physician disagrees with score, or wishes to add or modify documentation, they can click on headers for each section, which will take them to the areas in the patient’s chart.
Clicking on Submit button commits all the documentation on form into the EMR
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 16
Example: Contrast-Induced Nephropathy
• Identified as a concern
• Lack of specific subcommittee
• Small group of pharmacists + radiologists + system chief for radiology
• Develop consensus guideline/treatment algorithms
• P&T approval/Site-System Radiology buy-in
• Publish standards/education
• Engage CPOE system/IT technology
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 17
All radiology orderables with contrast will be converted to an order set. This set will now contain the radiology orderable as well as the “Contrast Induced Nephropathy Interventional” order set. This order set was added so that it would be more efficient and more likely to have appropriate interventional therapy ordered.
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 18
If the prescriber determines that the patient is at risk for a contrast induced nephropathy (CIN) and/or has a history of allergy based on the factors listed, they can choose to open the CIN order set and place additional orders.
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 19
Other (Potential) System Programs
• Quality Improvement – System quality improvement initiatives – Medication Use Evaluation
• Device/Supply Acquisition
• Nursing-Pharmacy
• Technology Assessment/Implementation • Medication Safety
Advantage – Using System P&T as Template
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 20
System Medication Safety
• System-wide medication safety program utilizing identical structure as system P&T (dual reporting relationship to System P&T and System Quality Council)
• System approach – Data aggregation/trending – Safeguards within the electronic health record – Review/response to medication safety alerts (e.g., FDA, ISMP) and TJC
NPSGs
• Site approach – Review of all site MVs/ADRs/implementation of select initiatives – Identification of site specific issue -> evaluation of other sites – Specific med safety committee v. site nursing/pharm committee
Advantage – Using System P&T as Template
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 21
System Medication Safety
• Review of monthly medication errors of high severity – site representative required to know case/follow-up → discussion whether
“one off” versus potential system/process error → applicable to other sites → monitor → decision if system intervention needed
• Examination of FDA, ISMP alerts – applicability to system/sites → intervention, if needed
• Annual review (staggered) of regulatory requirements – LASA medications; Tallman lettering; high alert medications
Advantage – Using System P&T as Template
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 23
Drugs Commonly Associated with Falls
Joint initiative between system medication safety and system patient safety committees with final approval by P&T and nursing leadership
Advantage – Using System P&T as Template
DRUGS YOU MAY EXPECT….. • Benzodiazepines (alprazolam, lorazepam) • Antidepressants (fluoxetine, venlafaxine, amitriptyline) • Anticonvulsants (pregabalin, tiagabine) • Sleep Aids (zolpidem, diphenhydramine) • Narcotic Analgesics (morphine, codeine, propoxyphene) • Muscle Relaxants (baclofen, cyclobenzaprine)
DRUGS YOU MAY NOT EXPECT….. • Antiarrthymics (procainamide, disopyramide, quinidine) • Digoxin • Diuretics (hydrochlorothiazide, furosemide) • ACE Inhibitors (lisinopril, captopril) • Nitrates
***LOOK FOR THE YELLOW WRIST BAND***
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 24
List of medications and dates here
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 25
System Infection Prevention
• System-wide infection prevention team utilizing same structure as P&T
• System approach – Data aggregation/epidemiological trending – Safeguards within the electronic health record – Review/response to infection prevention national initiatives – Regulatory readiness
• Site approach – Site infection prevention teams responsible for implementation of
select system initiatives and site-determined needs – Identification of site specific issue -> evaluation of other sites
Advantage – Using System P&T as Template
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 26
Intended Use Patient Age Product
INPATIENT USE
Flu vaccine Protocol Product >36 months Fluzone QIV 0.5 ml vial, syringe, MDV
6 – 35 months Fluzone QIV 0.25 ml syringe
High dose - per MD or employee request
>65 years Fluzone TIV High Dose 0.5 ml syringe
OUTPATIENT USE (EMPLOYEE HEALTH, OP CLINICS)
Intradermal – per pt request 18 – 64 years Fluzone QIV 0.1 ml intradermal
Patient with egg allergy >4 years Flucelvax QIV 0.5 ml syringe
TIV – site requested option >4 years Fluvirin TIV MDV
Example: Influenza Vaccination Protocol
• Standardized flu vaccine formulary products and prescribing for inpatients, OP clinics and employees − Collaboration with pharmacy, infection control, employee health and supply
chain
• Implemented flu vaccine nursing protocol for inpatient use • Flu vaccine product formulary:
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 28
Patient Location
Medical Record #
Patient Name
Task Status
Date/Time Mnemonic Order Details
XSS42 12345689 Test, One Complete Completed 3/1/2017 09:00 EST
Influenza Vaccination Risk Assessment
3/1/2017 04:49:29 EST Order entered secondary to patient admission
XSS18 12457888 Test, Two Pending Scheduled 3/1/2017 11:40 EST
Influenza Vaccination Risk Assessment
3/1/2017 11:40:14 EST Order entered secondary to patient admission
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 30
Example: System Pharmacy Policies
• Facilities will adopt system policy and delete hospital-specific policy
• Implementation questions: – System policy cover page
! IU Health logo and facility logo ! Site specific signatures ! Site specific approval dates
– System policy signature page ! Chair of SPTC ! System Pharmacy Vice President/Chief Pharmacy Officer ! System committee approval dates
System Medication Use Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 31
System Medication Management Initiatives
• Purpose: This policy outlines the types of system medication management initiatives that may be developed
• System initiatives types: – Guidelines – Interchanges – Medication protocols – Pharmacy protocols – Restrictions
• Outlines procedures for each initiative type: – Purpose – Approval – Notification to prescriber – Prescriber responsibilities – Pharmacist responsibilities
System Pharmacy Policy
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 32
Lessons Learned System Medication Use Policy
• Standardizing practice across system
• Long turnaround time for review/implementation − Site → Subcommittee→System→Implementation
• Complexity of implementation at multiple facilities – FTE mix / varying processes / equipment – Electronic health record/CPOE system
• Order set review and build processes (rogue hospitals “bootlegging” order sets)
• Lack of support for system by hospital leadership
© Copyright Visante, Inc. All rights reserved | www.visanteinc.com 33
Challenges / Barriers System Medication Use Policy
• Trust/Engagement • Time/compensation for prescriber involvement • “Who” is the expert??? • Sense (real or perceived) that certain sites dominate • How do you balance efficiency at getting the work done
with making sure that everyone has a voice and is involved in the decisions?
• Once you establish the system P&T, what is the role of the site P&T Committees? – Are quality and safety issues (error reports, ADRs, quality
improvement initiatives) addressed at a system level, the site level, or both?
• “Town vs Gown”